.png)
TAIPEI, Taiwan, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Primo Biotechnology ("Primo") has announced a strategic partnership with SHINE Technologies, LLC ("SHINE"), a global leader in nuclear medicine production. This agreement grants Primo exclusive distribution rights for Ilumira™ (n.c.a. lutetium-177, Lu-177) in Taiwan and additional sales rights in Japan, South Korea, and Singapore. The collaboration aims to accelerate advancements in radioligand therapy (RLT), improving access to cutting-edge cancer treatments in the Asia-Pacific region.
Ilumira™ offers a transformative solution in nuclear medicine, enabling precise and effective treatments for challenging tumors. Primo’s comprehensive solutions will address the growing demand for advanced cancer therapies, from early diagnosis to late-stage treatment.
Under the partnership, Primo will gain priority access to SHINE’s therapeutic isotopes, ensuring a reliable supply for emerging nuclear medicine applications. SHINE’s Cassiopeia facility, North America’s largest n.c.a. Lu-177 production site, is expanding to meet the increasing global demand, strengthening SHINE’s position as a leading supplier and enhancing Primo’s market presence.
“This collaboration marks a pivotal step in bringing precision and hope to patients across Asia-Pacific,” said Dr. Ya-Yao Huang, CEO of Primo Biotechnology. “By partnering with SHINE, we ensure a stable supply of high-quality isotopes and advance cancer care in the region.”
About SHINE Technologies
Based in Janesville, Wisconsin, SHINE specializes in the production of n.c.a. Lu-177 and other medical isotopes. Through innovative fusion technology, SHINE is advancing cancer treatment and diagnostics while exploring applications in healthcare and sustainable energy. Learn more at www.shinefusion.com.
Media Contact:
shine.fusion@highwirepr.com
About Primo Biotechnology
Primo Biotechnology is a leader in Asia’s nuclear medicine sector, dedicated to developing and delivering high-precision radiopharmaceuticals. Committed to personalized cancer care, Primo’s vision, Future in Precision, drives its mission to improve healthcare outcomes. Visit www.primobt.com for more information.
Media Contact:
Primo Biotechnology Co., Ltd.
Sunny Chen
Marketing Manager
sunny.chen@primobt.com
